In guidance published in the American College of Cardiology publication Cardiology Magazine, cardiologists from Oregon Health & Science University and Indiana University recommend clinicians who treat COVID-19 patients with the malaria-antibiotic drug combination also consider monitoring those patients for ventricular arrhythmia, which involves the lower heart chambers beating quickly and irregularly and can lead to cardiac arrest.
Stecker and colleagues recommend clinicians who treat COVID-19 patients with the drug combination also monitor patients for dangerous arrhythmias. However, they acknowledge limited resources could make monitoring a challenge.
Read more at: https://neurosciencenews.com/coronavirus-hydroychloroquin-heart-16065/